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(Dietzsch and Parker, 2002). In the Centane district of the Transkei, the ASIR 
was reported as 89.0 per 100,000 for males (Marasas, 2001). A population based 
cancer register of the Umtata region of the Transkei between 1996 and 1999 
indicated that the ASIR for OC was 95.3 per 100,000 for males and 54.4 per 
100,000 for females (Mugwanya et al., 2001). The reasons for the confined 
geographical distribution are not well understood at present. 
Fig 1.1. Geographic distribution and annual incidence of OC per 100000 males. Numbers 
on the map indicate region specific averages (Hamilton and Aattonen, 2000) 
The two main histological subtypes of OC are adenocarcinoma (ADC) and 
squamous cell carcinoma (SCC). other types such as mucoepidermoid 
carcinoma, small cell carcinoma, sarcomatoid carcinoma and melanoma occur 
infrequently (Lam, 2002). Correct histological classification of cancers is very 
important, since their development is influenced by different aetiological factors. 
ADC is associated with gastric reflux and Barrett's oesophagus, a condition in 
which the normal squamous cells lining the oesophagus are replaced by 
metaplastic columnar epithelium. ADC is not related to smoking or alcohol. It 
occurs primarily in developed countries and is much less common than SCC 
(Meltzer, 1996; Kim et al., 1997). ADC develops mostly in the lower region of the 
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RARf1.4 lacks part of the 
ligand independent 
transactivation domain 
RARr..' lacks part of the 
ligand independent 
transactivation domain as 
well as part of the DNA 
binding domain 
Fig. 2.1. Schematic representation of the generation of different isoforms of human RARr.., 
including (A) gene structure, (8) the different transcripts transcribed from P2 (C) the structural 
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One-step reverse transcription PCR was carried out using the GeneAmp EZ rTth 
RNA PCR Kit (Applied Biosystems, New Jersey). rTth is a recombinant 
thermostable enzyme that has both reverse transcriptase and polymerase 
activity. Hot start multiplex PCR was used to amplify a 721 bp region of the 
RAR~2 transcript and a 276bp region of the low density lipoprotein receptor 
(LDL-R) transcript, with the latter transcript serving as an internal control for the 
PCR reaction and RNA integrity. The primers used for the amplification were 
described by Widschwendter et al. (2000) (sequences are included in appendix 
1). They spanned introns to eliminate the possibility of amplification of 
contaminating genomic DNA, and the forward primer for RARB2 lay within the 
357bp region that is spliced 'from the RARB4 transcript, in order to make the 
reaction specific for the amplification of RARr.,2. The location of primer 
sequences is shown schematically by the position of red arro s in figure 2.3. 
Exons of RAR~4 
transcript 
357bp exclse~ from ~RN~ I( 
by ""emaINe Splicing I 
Exons of RAR~2 
transcript 
Fig. 2.3. Transcripts of RARB4 and RARB2, showing position of primers 
(red arrows) as described in text (Widschwendter et al., 2000) 
The RT-PCR reaction was carried out in a total volume of 50~1 including 1 ~g 
RNA, 5~1 10x EZ buffer, 300~M of each dNTP, 0.45~M of each primer, 2.5mM 
manganese acetate, and 5 units of rTth polymerase. The thermocycling was 
carried out in a GeneAmp PCR system 2700 (Applied Biosystems) under the 
following conditions: 
Reverse transcription at 65°C for 40 minutes; denaturation at 94°C for 90s; 
eighteen cycles of 94°C for 45s, 65°C for 30s, 72°C for 60s; five cycles in which 
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Fig. 2.4. Quanlilation of RAR~2 RNA in OSCC cell lines, RT-PCR was carried oul as described 
in seclion 2,2.2, and the PCR producls were separaled on 2% agarose gel. Cells had been 
trealed as follows: lane 1: 5-Aza-dC for five days; lane 2: ATRA for 1 day; lane 3: 5-Aza-dC for 
five days followed by ATRA for 1 day; lane 4: DMSO for 1 day; lane 5: No RNA conlroi. The 
721bp band is Ihe amplification product of RAR~2, The internal control is a 276bp fragment of the 











2.3.2 Northern blot analysis 
In order to confirm the results of the RT-PCR experiment, Northern blot analysis 
was employed. The primary data are shown in figure 2.5. 
0 
0 
.., '" 0 0 <D N 0 0 '" .... 0 '" 0 u 0 UJ UJ 0 UJ
I I I "' OJ I ~ ~ ~ ~ >- <;; ~ '" 
T T T T C T C T C 
RAR~ 
18S rRNA 
Fig. 2.5. Northern blot analysis of RARI1 expression in untreated (C) , or 5-Aza-dC and ATRA 
treated (T) OSCC cells. 1 OlJg of RNA was separated on a gel, transferred to nitrocellulose and 
probed with an RARl12-specific DNA probe. The blot was subsequently probed for 18S rRNA 
levels for normalization. 
In almost all the cell lines, the signal was stronger in the treated lane than the 
control lane. The only exception was KY8E70, where 188 rRNA levels show that 
unequal loading is responsible for the apparent decrease in RAR!3. expression on 
treatment. In KY8E30, the signal was extremely weak for both 5-Aza-dC treated 
and untreated cells, which made accurate quantitation difficult. 
Values generated by densitometric quantitation of the RAR!3. signals on 
autoradiographs were divided by the values obtained for an 188 loading control 
on the same blots to standardize for loading. The results are presented 
graphically in figure 2.6. 
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-357 GCAGGCGGAA CACCGTTTTC CAAGCTAAGC 
-307 AAAGGGAGAG AAGTTGGTGC CCAGGAGCAG 
-257 CCTCCCCTGC TCATTTTMA AGCACTTCTT GTATTGTTTT TAAGGAGAGA 
·207 AAT AGGAAAG CTCTCTGGCT 
·157 GTCTGCTTTT GCAGGGCTGC TGGGAGTTTT TMGCTCTGT GAGAATCCTG 
·107 GGAGTTGGTG ATGTCAGACT AGTTGGGTCA TTTGAAGGTT 
·57 GTAGGGTTCA T A7TAGGCAAT TCAATCTTTC 
-7 ATTCTGTGTG ACAGAAGTAG TAGGMGTGA GCTGTTCAGA GGCCAGGAGG 
43 
93 GAGGACTGGG 
143 CACC*GTC*GGG GGAAGGCTTT TTGCAAGCAT 
193 TTACTTGGAA GGAGAACTTG GGATCTTTCT GGGAACCCCC C*GCCCC*GGCT 
243 GGA TTGGCCG AGCMGCCTG GMM TGGTA AATGATC 
I-'rr,rnr"".r P2 region of RAR[l, gene from cultured OSCC cells showing cytosine 
in WHC01; C'= in in both WHC01 
and KYSE70. TATA box is shown in italics. 
by 
was lines as 
was a 
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-357 GCAGGCGGAA CACCGTTTTC CAAGCTAAGC CGCCGCAAAT AAAAAGGCGT 
-307 AAAGGGAGAG AAGTTGGTGC TCAACGTGAG CCAGGAGCAG CGTCCCGGCT 
-257 CCTCCCCTGC TCATTTTAAA AGCACTTCTT GTATTGTTTT TAAGGAGAGA 
-207 AATAGGAAAG AAAACGCCGG CTTGTGCGCT CGCTGCCTGC CTCTCTGGCT 
-157 GTCTGCTTTT GCAGGGCTGC TGGGAGTTTT TAAGCTCTGT GAGAATCCTG 
-107 GGAGTTGGTGATGTCAGACT AGTTGGGTCA TTTGAAGGTT AGCAGCCCGG 
-57 GTAGGGTTCA C~GAAAGTTC ACTCGg ATAT ATTAGGCAAT TCAATCTTTC 
-7 ATTg TGTGTG ACAGAAGTAG TAGGAAGTGA GCTGTTCAGA GGCCAGGAGG 
43 GTCTA TTCTT TGCCAAAGGG GGGACCAGAA TTCCCCCATG ~GAGCTGTTT 
93 GAGGACTGGG ATGC.Q.GAGAA CGCGAGCGAT CCGAGCAGGG TTTGTCTGGG 
143 CAC.Q.GTC.GGG GTAGGATCCG GAA.Q.GCATTC GGAAGGCTTT TTGCAAGCAT 
193 TTACTTGGAA GGAGAACTTG GGATCTTTCT GGGAACCCCC ~GCCCCGGCT 
Fig. 2.8. Sodium bisulfite genomic sequencing of WHC03 RARB2 promoter region. 
Methvlated cvtosines shown in red, underlined 
Sodium bisulfite genomic sequencing was also used to determine the 
methylation status of the RAR~2 promoter in primary OC samples compared to 
normal tissue samples. Out of 11 primary tissue samples, only one patient 
showed methylation of cytosine bases in the promoter region of RAR~2, as 
shown in figure 2.9. 
-357 GCAGG.Q.GGAACACCGTTTTCCAAGCTAAGCCGCCGCAAATAAAAAGGCGT 
-307 AAAGGGAGAG AAGTTGGTGC TCAACGTGAG CCAGGAGCAG CGTCCCGGCT 
-257 CCTCCCCTGC TCATTTTAAA AGCACTTCTT GTATTGTTTT TAAGGAGAGA 
-207 P-AT AGGAAAG AAAACGCCGG CTTGTGCGCT CGCTGCCTGC CTCTCTGGCT 
-157 GTCTGCTTTT GCAGGGCTGC TGGGAGTTTT TAAGCTCTGT GAGAATCCTG 
-107 GGAGTTGGTG ATGTCAGACT AGTTGGGTCA TTTGAAGGTT AGCAGCCCGG 
-57 GTAGGGTTCA CCGAAAGTTC ACTCGCATAT ATTAGGCAAT TCAATCTTTC 
-7 ATTCTGTGTG ACAGAAGTAG TAGGAAGTGA GCTGTTCAGA GGCCAGGAGG 
43 GTCT A TTCTT TGCCAAAGGG GGGACCAGAA TTCCCCCATG ...QGAGCTGTTT 
93 GAGGACTGGG ATGCCGAGAA gGgGAGgGAT C~GAGCAGGG TTTGTCTGGG 
143 CACCGTCGGG GT AGGATCCG GAA~GCA TT~ GGAAGGCTTT TTGCAAGCAT 
193 TTACTTGGAA GGAGAACTTG GGATCTTTCT GGGAACCCCC ~GCCCCGGCT 
Fig. 2.9. Sodium bisulfite genomic sequencing of DNA from tumour samples. The TATA box is 
shown in italics; point mutations of four different patients are shown in red (each mutation being 




































2.3.4 Methylation Specific peR (MSP) 
MSP was used as an alternative method to determine the frequency of promoter 
methylation observed in primary tissue samples, thus avoiding the pitfalls 
associated with cloning DNA prior to sequencing. This technique involves the use 
of primers that are specific for either methylated or unmethylated DNA after 
sodium bisulfite modification. Optimisation of the peR reaction was performed on 
DNA from cell lines, before using valuable DNA from tumour and normal 
oesophageal specimens. 
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Fig. 2.10. Ethidium bromide stained agarose gel of peR products generated by MSP. 
MSP was performed on sodium bisulnle treated DNA, using primers specific for either 
methylated or unmethylated DNA as described in section 2.2.5. Beta-actin was used as a 
positive con tral. 
For most of the cell lines (except KYSE180 and KYSE520) both methylated (M) 
primers and unmethylated (U) primers amplified the 146bp region of the RARP.,2 
promoter. Although one would not expect both methylated and un methylated 
promoters to exist within a cell line, epigenetic regulation is a very variable 
mechanism of transcriptional control. The levels of methyl transferases vary 
throughout the cell cycle (Szyf and Detich, 2001). The variation between 
methylated and unmethylated DNA may therefore be a reflection of differences 
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analysis) and protein (determined by Western blot analysis) do not correlate. 
Chen et al. (2002) reported a similar finding in breast cancer cell lines. The 
Western blot analysis demonstrated that involvement of other RAR~ isoforms did 





















Fig. 2.11 . Western blot staining for RARr.. F domain in OSCC cell lines. Western blot was carried 
out as described in section 2.2.6. Coomassie stained gel (A) shows equal loading of protein in all 
lanes, while Western blot with an antibody specific for the F domain of RARB, conserved in all 
isoforms (8) shows expression of a single RARB isoform in three OSCC cell lines. 
Another mechanism that could possibly playa role in the downregulation of 
RAR~2 is the deacetylation of histones in the region of RAR~2 P2. Sirchia et al. 
(2002) reported that RAR~2 can be reactivated by histone acetylation in breast 
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3.1 .2 Trio function 
Trio was given its unusual name on account of its three important characteristic 
functional domains. These are two DH domains, designated DH1 and DH2, and a 
C terminal serine/threonine kinase domain, as shown in figure 3.2. In addition, it 
has several spectrin-like repeats, a PH domain and an SH3-like domain in 
tandem with each DH, and an immunoglobulin-like domain (Ig). The assortment 
of functional domains in Trio has lead to the hypothesis that Trio may be involved 





Fig. 3.2. Depiction of Trio protein showing important domains, including those from which its 
name is derived: DH1 and 2 (Dbl-homology domains) and SKinase (serine/threonine kinase 
domain) (Oebant et at, 1996). 
Trio has been shown to playa vital role in the outgrowth of neurons and guiding 
the direction of the neuron to its target (Bateman and Van Vactor, 2001). Mice 
that do not express Trio die during late embryogenesis. The embryos exhibit 
skeletal muscle defects as well as disorganization of cells within the 
hippocampus and olfactory bulb of the brain, although overall brain structure is 
not affected. This suggests that Trio is involved in the control of neural 
development on a fine scale, once the gross morphology of the brain has been 
established (O'Brien et aI., 2000). 
Estrach et al. (2002) clearly implicated Trio as a component of the nerve growth 
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28S ----1~i 
Fig, 3.3. Northern blot of RNA isolated from tumour (T) or 
adjacent normal (N) tissue samples probed with Trio-
specific probe, 5IJ.g of total RNA from patients number 64 
and 124 was immobilised on the membrane. 
Northem blot analysis of osee cell line RNA was perfonned in order to optimise 
the technique, and investigate the relative abundance of Trio in different cell 
lines. 10).l,g of RNA was run on a gel, blotted and probed as described in 
Appendix 1. osee cell lines and cell lines of other cancers were used. Three 
cervical cancer cell lines (SiHa, a squamous cell carcinoma; HeLa, 
adenocarcinoma; and ME180. an epidennoid carcinoma) a breast epithelial 
adenocarcinoma cell line (MDA-MB-231) and a neuroblastoma cell line (SK-N-
SH) were included in the study. KYSE520 was run again on the second blot to 
facilitate comparison across the different membranes, as shown in figure 3.4 A. 











Using 18S to correct for loading differences, the autoradiographic data was 
quantified using a densitometer (Chemi-Imager 5500, Alpha Innotech Corp.) and 
analysed using Prism software. Figure 3.4 (B) below shows a graphical 
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Fig. 3.4. Northern blot of 1 O~g cell line RNA probed with Trio-specific probe, and an 
185 rRNA specific probe, for normalisation. Auloradiographic data shown in (A) was 
quantitated by densitometer and the normalised data are represented graphically in 
(8). 
From this result it was determined that KYSE520 would be a good candidate cell 
line for RNAi experimentation since it expressed the highest levels of Trio of all 
the OSCC cell lines tested. However, HeLa and SiHa also expressed Trio at 
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Table 3.1. Results of transient FuGENE transfection of KYSE osee cell lines. are 







































Fig. 3.5. Oesophageal tissue sections stained with Trio antibody. (A) shows a section of normal 
epithelial tissue, magnified in (8). Some normal cells exhibit cytoplasmic staining with the Trio 
antibody, as indicated with arrows. (C) shows a section through smooth muscle of the 











3.3.4 Western blot analysis 
Western blot analysis was used to detect Trio protein in cell line Iysates, and 
determine the specificity of the anti-Trio antibody. A positive control for the 
antibody consisted of lysate of COS1 cells that had been transiently transfected 
with the Trio gene (supplied with the antibody). Western blot analysis revealed a 
number of very strong bands in each lane on the autorad, shown in figure 3.6 
below. The band corresponding to Trio, as indicated by the positive control, was 












WHC01 KYSE70 KYSE30 
A B A B __ .... ~r--...,:..;--,......,;;..-. 
• 
Fig. 3.6. Western blot of cell lysate from 3 osee cell lines with anti-Trio antibody. Protein was 
separated on a 5-15% gradient polyacrylamide gel. Different quantities of protein were loaded in 
each lane to optimise the level needed for Trio detection. The amount of protein loaded are as 
follows: WHC01 (A) 711-1g (8) 1421-1g; KYSE30 (A) 471-1g (8) 941-1g; KYSE70 (A) 611-1g (8) 122\.1g In 
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efficiently screen a large sample size. A technique such as 
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Fig. 3.8. Level of Trio expression in normal and adjacent tumour 
specimens from four OC patients as assessed by real-time PCR 
As previously discussed, the use of adjacent normal samples for comparison in 
an assay of this type is problematic due to the possibility of sample 
contamination. Since carcinogenesis is a multistep process, microscopic 
examination of tissue is not sufficient to identify individual cells that are at 
intermediate stages of transformation. It is thus possible that normal samples 
may contain a relatively high proportion of cancerous cells and vice versa. An 
alternative approach is obtaining samples from unpaired, unsymptomatic normal 
subjects. While obtaining biopsies from such a sample group would be difficult, 
the possibility of obtaining tissue from cadavers is being investigated, although 
this option has its own set of associated problems. 
3.4 Summary 
Although only a small sample was tested, the results suggest that Trio may be 
overexpressed in a subset of oe patients. Due to several complications, we were 
unable to fulfill the aims of determining Trio levels in a large number of oe 
patients and the effect of exogenously expressed Trio on cells in vitro. However, 












































carboxy-tenninal residues show divergence which may be related to distinctive 
functions of the proteins (Kruh et aI., 1990). 
I = Proline rich region 
Arg 
o =Nuclear localisalion Signal 
c-Abl 
• 
32% 90% 94% 29% I 26% I 57% I 
Fig. 4.1. Representation of human ARG tyrosine kinase showing percentage homology to 
human c-Abl. SH2 and SH3 are Src homology domains, involved in protein-protein 
interactions. The two C terminal domains function in binding and bundling of filamentous 
(F) and globular (G) actin, and the F domain of both proteins contains a nuclear export 
signal motif. The alternate unmyristolated (A) or myristolated (8) N terminal domains are 
shown (adapted from Pendergast, 2001). 
Although ARG is expressed at high levels in the brain, both ARG and c-Abl are 
expressed in a wide variety of tissues (Perego et al., 1992). Another similarity 
between c-Abl and ARG is the fact that both are expressed as two different 
transcripts, that result from alternative splicing. The transcripts are designated 1A 
and 'I B, and differ at the 5' end of the transcript. They encode two proteins that 
differ at the amino termini (Kruh et al., 1990). In both c-Abl and ARG, the 1 A form 
of the protein is not myristolated, whereas the 1 B forms have been found to be 
myristolated at Gly-2, facilitating interaction with the cell membrane. However, 
mutation of this glycine residue had no effect on the subcellular localisation of 













































































4.2. Molecular structure of Gleevec™ 
I lu cancer 
in cancer 
Table 4.1. of Gleevec for various kinases. Concentrations that give a 50% 





































4.1.4 Mode of action of 17 -AAG 
17 -AAG is a structural analogue of geldanamycin (molecular structure is shown 
in figure 4.4), a naturally occurring benzoquinone ansamycin antibiotic produced 
by Streptomyces hygroscopicus. It targets the molecular chaperone Hsp90. 
Hsp90 is responsible for stabilizing a variety of intracellular proteins and ensuring 
that they fold into the correct tertiary structure. By binding to the active site, 17-
AAG prevents Hsp90 from interacting with its client proteins by inhibiting its 
intrinsic ATPase activity. The unchaperoned, misfolded proteins are 
subsequently ubiquitinated and targeted for proteasomal degradation (reviewed 





OHJC OCONH z 
CHJ CHJ 
Fig. 4.4. Molecular structure of geldanamycin [R= CH30] 
and 17-AAG [R= H2C=CHCH 2NH] 
Several of the proteins 
which Hsp90 chaperones 
are involved in Signalling 
pathways leading to cell 
cycle progression and the 
prevention of apoptosis. 
Hsp90 may also play a 
role In stabilizing 
oncoproteins that are 
chimaeric or mutated in such a way that their expression enhances the malignant 
phenotype. Examples of such proteins are mutated p53, Bcr-Abl, HER2/neu 
(ErbB2) and the transcription factor Hypoxia-inducible factor-1 a (HIF1-a) (Isaacs 
et al., 2002; reviewed in Neckers, 2002). This makes Hsp90 an attractive target 
for chemical inhibition since it is indirectly crucial to a number of cancer signalling 
pathways. 17-AAG is currently in phase I clinical trials and has shown promising 
initial results. 
The potent antitumour activity of 17-AAG has been studied and described in a 
variety of cancers. In the human leukaemia cell line HL60, 17-AAG induces 

































































Table 4.2. Number of cells for MTT assay 
WHC01 3000 WHC03 3000 .......... -.-................... ] 
WHC05 3000 
WHC06 3000 
OM B ............ _.+ __ ....................... _ .... _ .. 3000 
F1107 3000 
KYSE30 6000 
KYSE70 6000 KYSE 180 ... _ .. 6::.0.'.0-:0
0







































































4.5. Effect of 1 
in 96 well 









-5.0 -2.5 0.0 
Log cone. 
and Gleevec on WHCO OSCC cell lines determined MTT assay. Cells 
concentrations of for 48 hours. Each the 















4.6. of KYSE OSCC cell lines to 1 CISIJlalm and 
MTT assay. Cells were in 96 well and treated with '1"""'''''' concentrations of 
48 hours. Each the average of four ,pr",r:CHP wells. 















Table 4.3. of and values for 8 osee cell lines values in pM). Where 
value was incalculable because of very concentration value 
in column indicates concentration at which drug was administered for drug cornbinCltion 
cancer were 
I\I1TT curves 












-, -6 -5 -4 -3 -2 -1 0 
cone. 
4.7. Effect of 17-AAG on normal human fibroblast cell DMB and F1107 cells 
were plated in 96 well plates and treated with concentrations of 17 -AAG in 
quadrupilcate. After 48 hours of drug treatment the effect of 17-AAG on cell proliferation 
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cone. of Gleevec 
4,8, MTEffect of Gleevec on K562 cell 




Cells were treated with 



























































I!!:i<J 10uM Gleevec 
_ 20uM Gleevec 
c::J Untreated 
c::J 10uM Gleevec 
_ 20uM Gleevec 
Fig. 4.9. Comparison of effect of Gleevec treatment on KYSE520 measured by (A) MIT assay 
and (B) Cell counting. Cells were treated with varying concentrations of Gleevec. MTT assay 
represents the average of four replicate wells, while cell counting data reflects the average of 
















CJ] 1 DuM Gleevec 
_ 2DuM Gleevec 
Fig. 4.10. Effect of Gleevec on cell number for two OSCC cell lines. Cells were 
treated with varying concentrations of Gleevec in 35mm dishes in triplicate. 




































4.11. Effne! of combinations on cell metabolism of 8 osee cell lines as measured by MTT assay. Cells were plated 











4.3.4 Western blot analysis 
Western blot analysis was carried out to determine the overall levels of tyrosine 
phosphorylation in untreated cells compared to those treated with Gleevec or 17-
AAG. It was hoped to deduce whether tyrosine kinases were significantly 
inhibited by either drug. The results of the Westem blot experiment are shown in 
fig ure 4.12 below. Coomassie staining of the protein gel after transfer showed 
that there was equal loading of protein in each lane (data not shown). 
WHC01 WHC05 WHC06 
l') 0 l') 0 l') 0 
~ 
Q) 
~ g! ~ 
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:2 0 c:i 
0 0 c:i 
0 0 c:i 
0 
220 kDa . ---. 
97 kDa ---. 
Fig. 4.12. Westem blot of cell line protein extracts with anti-Phosphotyrosine antibody. Celis 
were treated with 1 OflM Gleevec or 17-AAG at EC 50 concentration for 6 hours prior to protein 
collection in RIPA buffer with phosphatase inhibitors. 50fl9 of each cell lysate was 
electrophoresed on a 7.5% polyacrylamide gel and transferred to membrane. 
The Western blot shows that there was no significant inhibition of tyrosine 
phosphorylation by 17-AAG at ECso, or Gleevec at 101J.M. Gleevec had very little 
effect on cell proliferation, and it could therefore be argued that no change in 
phosphorylation should be expected. However the results for 17-AAG were 
surprising since it has causes a substantial reduction in cell proliferation at this 
concentration. There are three possible explanations for this result: the treatment 
time could be inappropriate to detect changes in kinase activity; the drug could 


































4,13, MTT assay results to confirm of 17-AAG used in Western blot. Cells were 
tested in 96 well plate format with the same aliquots of 17-AAG as used for Western blot 
experiment. Error bars represent SEM of 8 wells, 
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AGA GTT TGA TGG AGT 
GAC -3' 
was 
CCA TCC AAT CGG TAG TAG CG 
TTG GG -3' 
ATA ATT AAT CCA AAT AAT 
AAT CAT TT A CCA TTT TCC AAA 
TCG AGA ACG CGA GCG ATT CG 











AGA ATG TGA GTG ATT TGA 
AAC CAA TCC AAC CAA AAC AA 
GCT TCA GCT TCC TCA CAT GC 
GTC GGA GTC 
CTG GAA GAT GGT GAT GG-
GTA GTTGAT 
CC-3' 
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